A recent FDA expert panel, chaired by Commissioner Marty Makary, convened on July 17, 2025, to reassess the long-standing “black box” warning on menopause hormone therapy, particularly estrogen treatments.
The 12-member panel, comprised mainly of physicians supportive of hormone therapy, urged the FDA to remove the starkest warning for low-dose vaginal estrogen, arguing it no longer aligns with current evidence—and may be deterring women from much-needed care. Makary emphasized the potential health benefits of early hormone therapy initiation, including cardiovascular and cognitive advantages.
The black box warning originated from the 2002 Women’s Health Initiative (WHI), which revealed increased global risks—stroke, blood clots, breast cancer—among older women taking oral estrogen-progestin. But these findings were based on systemic, high-dose, combined hormones and involved women averaging 63 years old, well past the typical menopause onset.
Panelists highlighted that low-dose vaginal estrogen delivers minimal systemic estrogen, with studies showing negligible blood absorption and no heightened risk of stroke, thromboembolism, or cancer. Critics say bundling these treatments with high-dose oral regimens in warning labels is misleading and harmful.
Experts also emphasized that initiating hormone therapy within ten years of menopause—or before age 60—offers significant relief from vasomotor symptoms (hot flashes, night sweats), helps preserve bone density, and may reduce risks of osteoporosis and heart disease. A JAMA review last year supported using HRT in this demographic. Some data even suggests reduced risk of Alzheimer’s disease when therapy is started earlier.
Despite growing support, skepticism persists among health professionals. Critics caution that the panel lacked public comment and was heavily weighted with therapy advocates, raising concerns over bias and underrepresented dissenting voices.
Additionally, the heavy reliance on observational studies—not randomized trials—for low-dose vaginal estrogen has been flagged by experts worried about overestimating benefits.
Meanwhile, alternative non-hormonal treatments are gaining traction. Fezolinetant (brand name Veozah), a neurokinin‑3 receptor antagonist approved in 2023, has shown robust efficacy in reducing hot flashes for women who cannot pursue hormone therapy—especially those with cancer or cardiovascular concerns—though it carries a rare risk of liver injury requiring monitoring.
The FDA has not officially removed any labeling yet, but Commissioner Makary pledged a prompt review. The agency is expected to open a public comment period via the Federal Register next week and may revise warning labels, initially targeting low-dose vaginal estrogen.
Women experiencing moderate to severe menopausal symptoms—including hot flashes, night sweats, vaginal dryness, or sleep/mood disturbances—should consider consulting their healthcare providers about personalized treatment options. For many, the benefits of hormone therapy outweigh the risks when sensitivity to dose, delivery method, and timing (age or years since menopause) is properly accounted for.
READ MORE
